Tafamidis improves myocardial longitudinal strain in A97S transthyretin cardiac amyloidosis

Tafamidis improves myocardial longitudinal strain in A97S transthyretin cardiac amyloidosis

Background: Transthyretin cardiomyopathy (ATTR-CM) is a debilitating disease that has received much attention since the emergence of novel treatments. The Transthyretin Cardiomyopathy Clinical Trial showed that tafamidis, a transthyretin tetramer stabilizer, effectively reduced the declines in funct...

Full description

Bibliographic Details
Main Authors:	Yuan-Kun (Aden) Wu, An-Li Yu, Mei-Fang Cheng, Lung-Chun Lin, Ming-Jen Lee, Chia-Hung Chou, Chia-Tung Shun, Hsueh-Wen Hsueh, Jimmy Jyh-Ming Juang, Ping-Huei Tseng, Siao-Ping Lin, Mao-Yuan Su, Chi-Chao Chao, Sung-Tsang Hsieh, Cheng-Hsuan Tsai, Yen-Hung Lin
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-01-01
Series:	Therapeutic Advances in Chronic Disease
Online Access:	https://doi.org/10.1177/20406223231222828

Similar Items

Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study
by: Cheng-Hsuan Tsai, et al.
Published: (2023-09-01)

Reverse cardiac remodelling and dysfunction in A97S transthyretin cardiac amyloidosis after tafamidis treatment
by: Yuan‐Kun (Aden) Wu, et al.
Published: (2022-12-01)

Altered gut microbiota in Taiwanese A97S predominant transthyretin amyloidosis with polyneuropathy
by: Chieh-Chang Chen, et al.
Published: (2024-03-01)

Unique Phenotypes With Corresponding Pathology in Late-Onset Hereditary Transthyretin Amyloidosis of A97S vs. V30M
by: Hsueh-Wen Hsueh, et al.
Published: (2022-01-01)

Interdisciplinary Multidimensional Assessment of Transthyretin Amyloidosis before and after Tafamidis
by: Manuela Pennisi, et al.
Published: (2023-12-01)

Cardiac manifestations and prognostic implications of hereditary transthyretin amyloidosis associated with transthyretin Ala97Ser
by: Hsing-Jung Lai, et al.
Published: (2020-03-01)

Use of Technetium‐99m‐Pyrophosphate Single‐Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy
by: An‐Li Yu, et al.
Published: (2024-01-01)

Cardiomyopathy correlates to nerve damage in p.A117S late‐onset transthyretin amyloid polyneuropathy
by: Yen‐Hung Lin, et al.
Published: (2022-09-01)

Phenotypic expressions of hereditary Transthyretin Ala97Ser related Amyloidosis (ATTR) in Taiwanese
by: Hui-Ching Hsu, et al.
Published: (2017-09-01)

Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
by: Benjamin Li, et al.
Published: (2020-06-01)

Prognostic Impact of the Increase in Cardiac Troponin Levels during Tafamidis Therapy in Patients with Transthyretin Cardiac Amyloidosis
by: Makiko Nakamura, et al.
Published: (2023-07-01)

Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy
by: Marla B Sultan, et al.
Published: (2017-09-01)

A study protocol for an observational cohort investigating cardiac transthyretin amyloidosis flow reserve before and after Tafamidis treatment: The AMYTRE study
by: Bastien Vançon, et al.
Published: (2022-08-01)

Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years
by: Giampaolo Merlini, et al.
Published: (2020-02-01)

Clinical and genetic profiles of hereditary transthyretin amyloidosis in Taiwan
by: Hua‐Chuan Chao, et al.
Published: (2019-05-01)

Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild‐type transthyretin amyloid cardiomyopathy
by: Seiji Takashio, et al.
Published: (2023-08-01)

Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
by: Falcão de Campos C, et al.
Published: (2023-02-01)

Nerve pathology of microangiopathy and thromboinflammation in hereditary transthyretin amyloidosis
by: Shin‐Joe Yeh, et al.
Published: (2024-01-01)

Hereditary transthyretin amyloidosis
by: T. A. Adyan, et al.
Published: (2020-01-01)

Management of transthyretin amyloidosis
by: Adalgisa Condoluci, et al.
Published: (2021-10-01)

Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysisResearch in context
by: Jie Wang, et al.
Published: (2023-09-01)

Molecular dynamics simulation study of AG10 and tafamidis binding to the Val122Ile transthyretin variant
by: Kevin F. Morris, et al.
Published: (2020-03-01)

Transthyretin Cardiac Amyloidosis: Underrecognized in the Underrepresented
by: Douglas J. Leedy, et al.
Published: (2023-08-01)

Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort
by: Nath Pasutharnchat, et al.
Published: (2021-05-01)

Multiparametric Monitoring of Disease Progression in Contemporary Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Initiating Tafamidis Treatment
by: Svenja Ney, et al.
Published: (2024-01-01)

Erratum to: Management of transthyretin amyloidosis
by: Swiss Medical Weekly
Published: (2021-11-01)

Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy
by: Leslie Amass, et al.
Published: (2018-12-01)

EGCG-Mediated Protection of Transthyretin Amyloidosis by Stabilizing Transthyretin Tetramers and Disrupting Transthyretin Aggregates
by: Huizhen Zou, et al.
Published: (2023-09-01)

Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis
by: Hiroki Yamaguchi, et al.
Published: (2022-03-01)

Native T1 mapping in transthyretin amyloidosis.
by: Fontana, M, et al.
Published: (2014)

Native T1 mapping in transthyretin amyloidosis
by: Fontana, M, et al.
Published: (2014)

Diagnostic algorithm in transthyretin amyloidosis with cardiomyopathy
by: Mariana Gospodinova, et al.
Published: (2020-07-01)

A review of transthyretin cardiac amyloidosis
by: Jhawar Nikita, et al.
Published: (2023-03-01)

Transthyretin Amyloidosis Therapies: Guiding the Future
by: Alejandra González-Duarte
Published: (2021-01-01)

Modulation of the Mechanisms Driving Transthyretin Amyloidosis
by: Filipa Bezerra, et al.
Published: (2020-12-01)

Disease-Modifying Therapy for Transthyretin Amyloidosis
by: Nowell M. Fine, MD, SM
Published: (2020-11-01)

Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey
by: Juan González-Moreno, et al.
Published: (2023-12-01)

Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
by: Arnt V Kristen, et al.
Published: (2017-01-01)

Frailty in Older Patients with Transthyretin Cardiac Amyloidosis
by: Stéphanie Cazalbou, et al.
Published: (2023-12-01)

Coexistence of Light Chain and Transthyretin Cardiac Amyloidosis
by: Abhishek Gami, MD, et al.
Published: (2024-04-01)